Announcement • Jul 27
Liminatus Pharma, Inc. Receives Notice of Non-Compliance with Nasdaq Listing Rule As previously reported, on January 15, 2026, Liminatus Pharma, Inc. received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the Bid Price Rule) which requires listed securities to maintain a minimum bid price of $1 per share. Under the Nasdaq rules, the Company was provided a compliance period of 180 calendar days, or until July 14, 2026, in which to regain compliance with the Bid Price Rule. A hearing was held before the Nasdaq Hearings Panel (the Panel) on June 30, 2026 during which the Company requested an extension of the Company's period for regaining compliance with the Bid Price Rule. On July 20, 2026, the Company received a notice from Nasdaq indicating that the Company has not regained compliance with the Bid Price Rule and is not eligible for a second 180-day extension to regain compliance with the Bid Price Rule. The notice indicated that the Panel will consider this matter in their decision regarding the Company's continued listing on Nasdaq and that the Company should present its view with respect to the additional deficiency to the Panel in writing no later than July 27, 2026. The Panel has not yet issued a decision on the Company's continued listing. The Company plans to submit a timely written response to the Panel regarding the additional deficiency. There can be no assurance that the Panel will give the Company additional time to come back into compliance or that the Company will be able to regain compliance with the Minimum Bid Price Rule. This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. On July 13, 2026, the Company filed a definitive proxy statement with respect to the annual meeting of the Company's stockholders scheduled to be held on August 3, 2026 at 10:30 a.m. Pacific Time for the purpose of authorizing the Company's board of directors to approve a reverse stock split of the Company's common stock, among other things. Announcement • Jul 14
Liminatus Pharma, Inc., Annual General Meeting, Aug 03, 2026 Liminatus Pharma, Inc., Annual General Meeting, Aug 03, 2026. Location: offices of the company, 2251 stern goodman street, suite e, california 92833, fullerton United States Live News • Jul 01
Liminatus Pharma Revises InnocsAI Merger to Expand Oncology Cell Therapy Pipeline Liminatus Pharma amended its definitive merger agreement with InnocsAI to broaden its oncology cell therapy pipeline, with the transaction expected to close on 2 July 2026, subject to customary closing conditions.
The company describes the InnocsAI merger as a transformational step that widens its development portfolio and creates multiple potential avenues for long-term shareholder value in oncology cell therapy.
Liminatus Pharma shares trade at around $0.11, with the stock down 82.8% year to date, which frames the merger as a high-impact corporate event against a weak recent trading backdrop.
This deal shifts the story around Liminatus Pharma toward pipeline scale and optionality in oncology cell therapy, but it also concentrates execution risk around integrating InnocsAI and advancing a larger set of programs with limited market confidence currently reflected in the share price. 
